Compare BioNano Genomics Inc (BNGO) vs Lennar Corporation (LEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Lennar Corporation — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Lennar Corporation trades at $87.48 (market cap $21.05B). The key difference: Lennar Corporation is far larger — about 1541× BioNano Genomics Inc's market cap, and Lennar Corporation pays a 2.28% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | LEN | |
|---|---|---|
Market Cap | $13.66M | $21.05B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $142.40 |
52-Week Low | $1.06 | $81.84 |
Enterprise Value | $16.26M | $24.93B |
Dividend Yield | — | 2.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Lennar (LEN) trades at $85.70, up 0.12% today, with a neutral technical signal and bullish moving averages. The stock shows mixed earnings performance, missing EPS estimates in three of the last four quarters, while maintaining a modest dividend. Valuation ratios appear reasonable with a P/E of 13.72 and P/B below 1. Recent news highlights price volatility and analyst scrutiny amid housing market pressures.
LEN presents a cautious opportunity with undervalued metrics but faces headwinds from declining profitability and housing affordability challenges. Analyst consensus leans buy (46%) with a $84.30 target, near current price. Key risks include earnings misses, rising mortgage rates, and competitive threats from disruptors like Boxabl. Upside depends on execution improvement and market stabilization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →
